{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"}]}],"title":"Breast cancer (n=85)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.4","upperLimit":"10.7","value":"3"}]}],"title":"Non-small cell lung carcinoma (n=65)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.8","upperLimit":"20.2","value":"11"}]}],"title":"Colorectal cancer (n=74)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"}]}],"title":"Ovarian cancer (n=66)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"}]}],"title":"Prostate cancer (n=21)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.1","upperLimit":"16.7","value":"3"}]}],"title":"Multiple myeloma (n=31)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.2","upperLimit":"30.2","value":"6"}]}],"title":"Biliary tract cancer (n=16)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"5.3","value":"2"}]}],"title":"Other cancer (n=190)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.7","upperLimit":"4.7","value":"3"}]}],"title":"Overall (n=540)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"548"}],"units":"Participants"}],"description":"Formalin-fixed paraffin-embedded (FFPEs) tumor samples (at least 5 serially-cut, unstained, 5 micrometer \\[μm\\] sections) were collected from eligible participants who consented to participate in the study. FFPE tumor samples were either from archived sections (from the initial diagnosis of cancer) or from fresh biopsies that were performed according to local standards. Tumor samples were then sent to a central laboratory to identify activating BRAF V600 mutations. Identification of mutations was done using bidirectional direct Sanger sequencing procedure.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with solid tumors (other than metastatic melanoma or papillary thyroid cancer) or multiple myeloma who met the inclusion criteria and did not meet exclusion criteria of the study were enrolled and were evaluated for the presence of BRAF V600 mutations by collecting tumor samples or performing fresh biopsies according to local standards.","id":"OG000","title":"Participants With Confirmed Solid Tumors or Multiple Myeloma"}],"paramType":"NUMBER","populationDescription":"All the participants who were enrolled and were evaluable for the BRAF V600 mutations were included in the analysis. n is the number of participants with that type of cancer in the total population.","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Percentage of Participants With BRAF V600 Mutation Positivity in Tumor Samples by Cancer Type","type":"PRIMARY","unitOfMeasure":"percentage of participants"}